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Abstract
The discovery of peptides having high biological activity is very chal-
lenging mainly because there is an enormous diversity of compounds and
only a minority have the desired properties. To lower cost and reduce
the time to obtain promising compounds, machine learning approaches
can greatly assist in the process and even replace expensive laboratory
experiments by learning a predictor with existing data. Unfortunately,
selecting ligands having the greatest predicted bioactivity requires a pro-
hibitive amount of computational time. For this combinatorial problem,
heuristics and stochastic optimization methods are not guaranteed to find
adequate compounds.
We propose an efficient algorithm based on De Bruijn graphs, guar-
anteed to find the peptides of maximal predicted bioactivity. We demon-
strate how this algorithm can be part of an iterative combinatorial chem-
istry procedure to speed up the discovery and the validation of peptide
leads. Moreover, the proposed approach does not require the use of known
ligands for the target protein since it can leverage recent multi-target ma-
chine learning predictors where ligands for similar targets can serve as
initial training data. Finally, we validated the proposed approach in vitro
with the discovery of new cationic anti-microbial peptides.
Source code is freely available at http://graal.ift.ulaval.ca/peptide-design/.
∗sebastien.giguere.8@ulaval.ca
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1 Introduction
Drug discovery faces important challenges in terms of cost, complexity and in the
rapid discovery of promising compounds. A valuable drug precursor must have
high affinity with the target protein while minimizing interactions with other
proteins, in order to avoid side effects. Unfortunately, only a few compounds
have such properties and these have to be identified from an astronomical num-
ber of candidate compounds. Other factors, such as bio-availability, stability,
among many others have to be considered; but this combinatorial search prob-
lem by itself is very challenging (MEE et al., 1997). The process of discovering
novel compounds with both high bioactivity and low toxicity must therefore be
optimized.
Fortunately, in the last decade, machine learning and kernel methods (Scho¨lkopf and Smola,
2002; Shawe-Taylor and Cristianini, 2004) have been extremely effective at pro-
viding efficient learning algorithms for a wide range of application domains.
These methods provide novel way to find patterns in biological and chemical
data. These include the prediction of mutagenicity, toxicity and the anti-cancer
activity of small molecules (Swamidass et al., 2005). They are also used in the
prediction of protein-protein interactions (Ben-Hur and Noble, 2005), protein-
ligand interactions and the in silico screening of novel targets (Jacob et al.,
2008). This success can be mainly attributed to the inclusion of similarity func-
tions, known as kernels (Shawe-Taylor and Cristianini, 2004; Scho¨lkopf and Smola,
2002). The kernels incorporate valuable biological and chemical knowledge pro-
posed by biologists and, consequently, provide a natural and efficient way to
improve the accuracy of learning algorithms. However, the use of state-of-
the-art learning algorithms to design and enhance the pharmaceutical proper-
ties of known compounds have remained largely unexplored and unexploited
(Schneider, 2010; Damborsky and Brezovsky, 2009).
In the context of drug design, knowing if a ligand will interact with a par-
ticular protein is helpful. However, most potential ligands have low activity
and would not represent valid drug precursors. To predict more valuable in-
formation, recent work has addressed the task of predicting the bioactivity and
binding affinity between ligands and a target protein (Gigue`re et al., 2013a). For
instance, starting with a training set containing approximately 50 − 100 pep-
tides with their corresponding quantified activity (bioactivity, binding affinity,
etc) one can expect that a state-of-the-art kernel method will give a bioactiv-
ity predictor which is accurate enough to find additional peptides with higher
activity than the best ones in the original . This is possible, since each peptide
that possesses a small binding affinity contains information about subsequences
of residues that can bind to the target.
For novel and less studied targets, screening libraries remain the method of
choice for rapid ligand development. To fully exploit the great conformational
and functional diversity that is accessible with peptides, combinatorial chem-
istry is certainly the most powerful tool. A major asset of combinatorial peptide
libraries over classic combinatorial libraries, where the scaffold is fixed, is the
possibility to generate enormous conformational diversity as well as functional
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diversity using a randomized synthesis procedure. This chemical diversity and
functionality can be further enhanced by the inclusion of non-natural amino
acids. Furthermore, having a peptide scaffold can be very informative to screen
for similarities in peptidomimetics libraries. However, it is important to note
that combinatorial peptide chemistry cannot cover a significant part of the pep-
tide diversity when using more than a few amino acids. For example, 2g of a
one-bead one-compound combinatorial library composed of randomly-generated
peptides of nine residues will generate a maximum of six million compounds,
representing a vanishingly small fraction (less than 0.0016%) of the set of all
209 peptides. Consequently, it is almost certain that the best peptides will not
be present in the initial screening and most synthesized peptides will have low
bioactivity.
The drug discovery challenge is a complex combinatorial problem which
unfortunately cannot be solved using combinatorial chemistry alone. Many
have proposed to use combinatorial chemistry or existing databases to learn a
machine learning predictor to tackle this problem. The main motivation was
that, in silico prediction is fast and inexpensive and would ultimately accelerate
this costly process. Unfortunately, this effectively transforms the combinatorial
drug discovery problem into a equally hard optimization task which is sometime
know to be NP-Hard (Cortes et al., 2005). Indeed, predicting the bioactivity
of all possible ligands, then selecting the most promising ones, would require a
prohibitive amount of computational time. Heuristics and stochastic optimiza-
tion are generally the methods of choice when facing such tasks (Jamois, 2003;
Pickett et al., 2000). However, these time and resource consuming methods are
not guaranteed to find the optimal solution. In fact, because of the size of the
search space, stochastic optimization is likely to find a poor solution. The prob-
lem of finding the most active and specific ligand is still an open algorithmic
problem.
We propose, for a large class of machine learning predictors, an efficient
algorithm based on De Bruijn graphs to find the peptide of maximal predicted
bioactivity. This algorithm can be part of an iterative combinatorial chemistry
procedure that could speed up the discovery and the validation of peptide leads.
Moreover, the proposed approach can be executed without known ligands for
the target protein, since it can leverage recent multi-target machine learning
predictors where ligands for similar targets can serve as an initial training set.
Finally, we demonstrate the effectiveness and validate our approach in vitro by
providing an example of how anti-microbial peptides with proven activity were
selected.
2 Approach
2.1 The Generic String kernel
String kernels are similarity functions between strings, which are arbitrary se-
quences of characters. In our context, strings are composed of amino acids
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or nucleotides. Such kernels have been widely used in applications of machine
learning to biology. For example, the local-alignment kernel (Saigo et al., 2004),
closely related to the well known Smith-Waterman alignment algorithm, was
used for protein homology detection. It was observed that kernels for large
molecules such as proteins were not suitable for smaller amino acids sequences
such as peptides. Indeed the idea of gaps in the local-alignment kernel or the
Smith-Waterman algorithm is well suited for protein homology, but a gap of
only a few amino acids in a peptide would have important consequence on the
binding affinity with a target protein.
Many recently proposed string kernels have emerged from the original idea
of the spectrum kernel (Leslie et al., 2002) were each string is represented by
the set of all k-mers that are present. For example, PALI can be represented
by it’s set of 2-mers {PA,AL,LI}. As defined by the spectrum kernel, the
similarity score between two strings is simply the number of k-mers that they
have in common. For example, the spectrum similarity between PALI and
LIPAT would be 2, because they have two 2-mers in common (PA and LI).
To characterize the similarity between peptides, two different k-mer criteria
were found to be important. First, two k-mers should only contribute to the
similarity if they are in similar positions in the two peptides (Meinicke et al.,
2004). Second, the two k-mers should share common physico-chemical proper-
ties (Toussaint et al., 2010).
Meinicke et al. (2004) proposed to weight the contribution of identical k-
mers with a term that decays exponentially rapidly with the distance between
their positions. If i and j denote the positions of the k-mers in their respective
strings, the contribution to the similarity is given by
e
(
−(i−j)2
2σ2p
)
, (1)
where σp is a parameter that controls the length of the decay.
Toussaint et al. (2010) proposed to consider properties of amino acids when
comparing similar k-mers. This was motivated by the fact that amino acids
with similar physico-chemical properties can be substituted in a peptide while
maintaining the binding characteristics. To capture the physicochemical prop-
erties of amino acids, they proposed to use an encoding function ψ : Σ −→ Rd
where ψ(a) = (ψ1(a), ψ2(a), . . . ψd(a)), to map every amino acids a ∈ Σ to a
vector where each component ψi(a) encodes one of the d properties of amino
acid a. In a similar way, we can define ψk : Σk −→ Rdk as an encoding function
for k-mers, where
ψk(a1, a2, .., ak)
def
= (ψ(a1),ψ(a2), . . . ,ψ(ak)) , (2)
by concatenning k physico-chemical property vectors, each having d compo-
nents. It is now possible to weight the contribution of two k-mers a and a′
according to their properties:
e
(
−‖ψk(a1,..,ak)−ψ
k(a′1,..,a
′
k
)‖2
2σ2c
)
, (3)
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where ‖ · ‖ denotes the Euclidean distance.
More recently, the Generic String (GS) kernel was proposed for small biolog-
ical sequences and pseudo-sequences of binding interface (Gigue`re et al., 2013a).
The GS kernel is defined by
GS(x,x′, k, σp, σc)
def
=
k∑
l=1
|x|−l∑
i=0
|x′|−l∑
j=0
e
(
−(i−j)2
2σ2p
)
× e

−‖ψl(xi+1,..,xi+l)−ψl(x′j+1,..,xj+l)‖2
2σ2c


.
(4)
Hence, the similarity between string x and x′, as defined by the GS kernel, is
given by comparing their 1-mers, 2-mers, . . . up to their k-mers with the position
penalizing term of Equation (1) and the physico-chemical contribution term of
Equation (3). k, σp, σc are hyper-parameters used for tuning the GS kernel and
are generally chosen by cross-validation.
This Generic String kernel is very versatile since, depending on the chosen
hyper-parameters, it can be specialized to eight known kernels (Gigue`re et al.,
2013a): the Hamming kernel, the Dirac delta, the Blended Spectrum (Shawe-Taylor and Cristianini,
2004), the Radial Basis Function (RBF), the Blended Spectrum RBF (Toussaint et al.,
2010), the Oligo (Meinicke et al., 2004), the Weighted degree (Ra¨tsch and Sonnenburg,
2004), and the Weighted degree RBF (Toussaint et al., 2010).
In a recent study (Gigue`re et al., 2013a), the GS kernel was used to learn a
universal peptide-protein binding affinity predictor capable of predicting, with
reasonable accuracy, the binding affinity of any peptide to any protein using the
PepX database as the training set. The GS kernel has also outperformed the
current state-of-the-art methods for predicting peptide-protein binding affinities
on single-target and pan-specific Major Histocompatibility Complex class II
benchmark datasets and three Quantitative Structure Affinity Model benchmark
datasets. Recently, the GS kernel won the 2012 Machine Learning Competition
in Immunology (Gigue`re et al., 2013b). External validation determined that
an SVM classifier equipped with the GS kernel was the overall best method to
identify, given unpublished experimental data, new peptides naturally processed
by the major histocompatibility complex (MHC) Class I pathway. The proven
effectiveness of this kernel made it ideal to tackle the present problem.
2.2 The machine learning approach
In a binary classification setting, the learning task is to predict whether an
example has a specific property such as binding to a target molecule. In this case,
the training set consists of positive examples, those having the desired property,
and negative examples, those who do not. In a regression setting, the learning
task is to predict a real value that quantifies the quality of a peptide, for example,
its bioactivity, inhibitory concentration, binding affinity, or bioavailability. Such
values are generally obtained from in vitro or in vivo experiments.
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In this paper, each example will be of the form ((x,y), e), where x repre-
sents a peptide and y the drug target, which is typically a protein (but other
biomolecules could be considered). In the present regression context, e ∈ R
is a real number representing the bioactivity of the peptide x with the target
y. In classification, e ∈ {+1,−1} denotes if (x,y) has the desired property or
not. Since predicting real values is strictly more general than predicting binary
values, we focused on the more general case of real-valued predictors.
A predictor can be a function h that returns an output h(x,y) when given
any input (x,y). In our setting, the output h(x,y) is a real number that es-
timates the “true” bioactivity e between x and y. Such a predictor is said to
be multi-target since it’s output depends on the ligand x and the target y. A
multi-target predictor is generally obtained by learning from numerous peptides,
binding to various proteins, for example, a protein family. For this reason, it
can predict the bioactivity of any peptide with any protein of the family even
if some proteins are not present in the training data.
In contrast, a predictor hy(x) is said to be target-specific when it is dedicated
to predict the bioactivity of a specific (fixed) protein y and any peptide x. A
target-specific predictor is obtained by learning only from peptides binding to a
specific protein y. For this reason, it can only predict the bioactivity of peptides
for the target y. In this paper, we focus on the more general case of multi-target
predictors.
Given a training set {((x1,y1), e1), . . . , ((xm,ym), em)}, a large class of learn-
ing algorithms, produce multi-target predictors h with the output h(x,y) on an
arbitrary example (x,y) given by
h(x,y) =
m∑
i=1
αikY(y,yi)kX (x,xi) , (5)
where kY and kX are, respectively, the similarity functions between proteins
and peptides, and αi is the weight on the i-th training example. The weight
vector α
def
= (α1, . . . , αm) depend on the learning algorithm used, but many
algorithms produce prediction functions given by Equation (5), including the
Support Vector Machine, the Support Vector Regression, the Ridge Regression,
Gaussian Processes, . . . This makes our solution for drug design compatible with
these learning algorithms1.
Since we use the GS kernel, we have
h(x,y) =
m∑
n=1
βn(y)GS(x,xn, k, σp, σc) , (6)
were βn(y) = αnkY(y,yn).
1Note that all these learning methods require both kernels to be symmetric and positive
semi-definite. This is the case for the GS kernel.
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2.3 The combinatorial search problem
The general motivation for learning a predictor from training data is that once
an accurate predictor is obtained, finding druggable peptides would be greatly
facilitated. It is true that replacing expensive laboratory experiments by an in
silico prediction will reduce cost. However, peptides having an average bioac-
tivity do not qualify as drug precursors. Instead, we should focus on identifying
the most bioactive compounds. The computational problem is thus to identify
and rank peptides according to a specific biological function.
Let A be the set of all amino acids, and Al be the set of all possible peptides
of length l. Then, finding the peptide x⋆ ∈ Al that, according to h, has the
maximal bioactivity with y, amounts at solving
x⋆
y
= arg max
x∈Al
h(x,y) . (7)
This pre-image problem is known to be NP-Hard for several kernels (Ga¨rtner and Vembu,
2009). Since the number of possible peptides, grows exponentially fast with the
length l of the peptide, a brute force algorithm has an intractable complexity
of O(|A|l ·O(h)) where O(h) is the time complexity of computing the output of
the predictor h. Such an algorithm becomes impractical for any long peptides,
such as stapled peptides known to have up to 35 amino acids.
Stochastic methods such as Metropolis-Hasting are often used to optimize
such functions h. These methods are time consuming, highly dependent on
optimization parameters and have no guarantee on the solution found.
In the next section, we present an efficient algorithm to find the exact solu-
tion to the GS kernel pre-image problem. The time complexity of the proposed
algorithm is linearly dependent on l, yielding tractable applications for peptides
and proteins.
3 Methods
3.1 Finding the peptide of maximal bioactivity
In this subsection, we assume that we have in hand a prediction function h(x,y)
in the form of Equation (6). In this case, we will show how the problem of finding
the peptide x⋆
y
∈ Al of maximal bioactivity reduces to the problem of finding
the longest path in a directed acyclic graph (DAG). To do so, we will construct
a graph with a source and a sink vertex such that for all possible peptides
x ∈ Al, there exists only one path, which has length h(x,y), that goes from the
source to the sink. If the size of the constructed graph is polynomial in l, any
algorithm that efficiently solves the longest path problem in a DAG will also
efficiently solve the pre-image problem of the GS kernel.
A bipartite graph G = ((U, V ), E) is a graph whose vertices can be divided
into two disjoint sets U and V such that every edge in E connects a vertex in
U to one in V . For any integer i, let Gi = ((Ui, Vi), Ei) be the i-th De Bruijn
directed bipartite graph of some set. This means that for every sequence s ∈ Ak,
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there is a vertex in Ui with the tuple (s, i) as label and a vertex in Vi with the
tuple (s, i + 1) as label. Moreover, there is a De Bruijn edge ((u, i), (v, i + 1))
from (u, i) ∈ Ui to (v, i + 1) ∈ Vi if and only if the last k − 1 amino acids of
u are the same as the first k − 1 amino acids of v. Note that ∀i ∈ N, directed
edges in Gi only go from vertices in Ui to vertices in Vi. There are exactly |A|
edges that leave each vertex in Ui and there are exactly |A| edges that point to
each vertex in Vi. Moreover, for any chosen integer k, |Ui| = |Vi| = |A
k| and
|Ei| = |A
k+1|. Consequently, for each sequence in Ak+1, there is a single edge
going from a vertex in Ui to a vertex in Vi.
The union between bipartite graph Gi = ((Ui, Vi), Ei) and bipartite graph
Gi+1 = ((Ui+1, Vi+1), Ei+1) is defined to be the 3-partite graph
Gi ∪Gi+1
def
= ((Ui, Vi ∪ Ui+1, Vi+1), Ei ∪ Ei+1) ,
where vertices with the same label in Vi ∪ Ui+1 are merged.
More generally we define a n-partite graph as the consecutive union of n− 1
bipartite graphs:
Gn
def
= G1 ∪ . . . ∪Gn−1
def
= ((U1, V1 ∪ U2, . . . , Vn−2 ∪ Un−1, Vn−1), E1 ∪ . . . ∪ En−1) .
Consequently, there is a one-to-one correspondence between each sequence
of Ak+n−1 and each path u, . . . , v : u ∈ U1, v ∈ Vn−1 of length n in G
n.
Finally, we add to Gn a source vertex, labeled (λ, 0), connected to all vertices
in U1 and a sink vertex t connected to all vertices in Vn−1 (λ is the empty string).
The set of all possible paths going from the source (λ, 0) to the sink t give rise
to all sequences in Ak+n−1.
Using the definition of the GS kernel given at Equation (4) and the general
class of predictors given by Equation (6), we can rewrite the generic prediction
function as
h(x,y) =
m∑
q=1
βq(y)
k∑
p=1
|x|−p∑
i=0
|xq|−p∑
j=0
e
(
−(i−j)2
2σ2p
)
× e
(
−‖ψp(x[i+1],..,x[i+p])−ψ
p(xq [j+1]
,..,xq [j+p]
)‖2
2σ2c
)
.
For any string s of length k and any i ∈ {1, . . . , n}, we define
W (s, i)
def
=
m∑
q=1
βq(y)
k∑
p=1
|xq|−p∑
j=0
e
(
−((i−1)−j)2
2σ2p
)
× e
(
−‖ψp(s1,...,sp)−ψ
p(xq [j+1],..,xq [j+p])‖
2
2σ2c
) (8)
as the weight on edges ((s′, i − 1), (s, i)) where s′ ∈ Ak ∪ λ, s ∈ Ak, and
i ∈ {1, . . . , n} i.e. all edges of Gn except edges heading to the sink vertex t.
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When k > 1, edges ((s, n), t), heading to the sink vertex t, are weighted by the
function
Wt
(
(s, i), t
)
=
k−1∑
j=1
W (sj+1 . . . sk, n+ j) , (9)
otherwise, Wt
(
(s, i), t
)
= 0 when k = 1.
For n = |x| − k + 1, we can now write h(x,y) as
Wt
(
(xn, .., x|x|, n), t
)
+
n∑
i=1
W (xi, .., xi+k−1, i) .
Therefore, every path from the source to the sink in Gn builds a unique peptide
such that the estimated bioactivity of that peptide is given by the length of the
path.
The problem of finding the peptide of highest activity thus reduces to the
problem of finding the longest path in Gn. Despite being NP-hard in the gen-
eral case, the longest path problem can be solved by dynamic programming
in O(|V (G)| + |E(G|) for a directed acyclic graph given a topological order-
ing of it’s vertices. By construction, Gn is clearly acyclic and its vertices
can always be topologically ordered by visiting them in the following order:
(λ, 0), U1, . . . , Un, Vn, t. Since G
n has (n|A|k + 2) ∈ O(n|A|k) vertices and
(2|A|k + (n − 1)|A|k+1) ∈ O(n|A|k+1) edges, the complexity of the algorithm
will thus be dominated by the number of edges.
We propose an algorithm in O(n|A|k+1) = O((l − k + 1)|A|k+1) for solving
the pre-image problem of the GS kernel. Recall that k is a constant and l is
the length of the peptide we are trying to identify. Thus n = l − k + 1. Small
values of k are motivated by the fact that ‖ ψk(a1, .., ak) − ψ
k(a′1, .., a
′
k) ‖
2
is a monotonically increasing function of k such that Equation (3) vanishes
exponentially fast as k increases. Long k-mers will have negligible influence on
the dot product and the estimated bioactivity, explaining why small values of
k ≤ 6≪ l are chosen by cross-validation. Therefore, the time complexity of the
proposed algorithm is orders of magnitude lower than the brute force algorithm
which is in O(|A|l) since k ≤ 6 ≪ l in practice. The pseudo-code to find the
longest path in Gn is given by Algorithm 1 (supplementary material).
3.2 Ranking peptides by bioactivity
Ranking peptides according to their bioactivity will provide valuable informa-
tion with the potential of accelerating functional peptide discovery. Indeed, the
best peptide candidates can be synthesized quickly by an automated peptide
synthesizer and then tested in vitro. Such a procedure will allow quick in vitro
feedback and minimize turnaround time. Also, the best predicted candidates
can be utilized to predict a binding motif for a new target protein. Such a motif
should assist researchers in the early study of a target and for the design of
peptidomimetic compounds by providing residue preferences.
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In the previous section, we have shown how the problem of finding the pep-
tide of greatest bioactivity reduced to the problem of finding a path of maximal
length in the De Bruijn graph Gn. By using the same arguments, finding the
peptide with the second greatest activity reduces to the problem of finding the
second longest path in Gn. By induction, it follows that the problem of find-
ing the K peptides of maximal activity reduces to the problem of finding the
K-longest paths in Gn.
Unfortunately, this problem has not been studied much since the longest
path problem is generally NP-Complete. The closely related K-shortest paths
problem was first studied in 1957, but attracted most attention following the
work of Yen et al. (1989); Yen (1971). Yen’s algorithm was later improved
by Lawler (1972). Both algorithms are relatively simple as they use existing
shortest path algorithms such as Dijkstra’s algorithm to solve the K-shortest
paths problem.
By exploiting some restrictive properties ofGn, we show how Yen’s algorithm
for the K-shortest paths can be adapted to find the K-longest paths in Gn.
The time complexity of the resulting algorithm, given in Section 6.2 of the
supplementary material, is competitive with the latest work onK-shortest paths
algorithms (Eppstein, 1998; Brander and Sinclair, 1995).
3.3 From K-longest paths to motif
It is easy to use the K-longest paths algorithm to efficiently predicts a motif by
simply feeding the K peptides to an existing motif tool. Here, the motif is a
property of the learned model h(x,y) as opposed to a consensus among known
binding sequences.
When the learned model h(x,y) is a multi-target model, it is then possible
to predict affinities for proteins with no known ligand by exploiting similarities
with related proteins. In this case, it is feasible to predict a binding motif for a
target with no known binders. To our knowledge, this has never been attempted
successfully.
3.4 Protocol for split and pool peptide synthesis
Split and pool combinatorial peptide synthesis is a simple but efficient way
to synthesize a very wide spectrum of peptide ligands. To synthesize several
peptides of length l using the 20 natural amino acids, the standard approach
is to use 20 reactors for natural amino acids and a pooling reactor. At every
step of the experiment, all reactors are pooled into the pooling reactor which is
then split in equal proportions back into the 20 amino acids reactors. Within
this standard approach, each peptide in Al has an equal probability of being
synthesized. Since the number of polystyrene beds (used to host every peptide)
is generally orders of magnitude smaller than |A|l, there is only a vanishing small
fraction of the peptides in Al that can be synthesized in each combinatorial
experiment.
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Clearly, not every peptide has an equal probability of binding to a target.
More restrictive protocols have been proposed to increase the hit ratio of this
combinatorial experiment. For example, one could fix certain amino acids at
specific positions or limit the set of possible amino acids at this positions (for
example, only use hydrophobic amino acids). Such practice will impact the
outcome of the combinatorial experiment. One can probably increase the hit
ratio by modifying (wisely) the proportion of amino acids that can be found at
different positions in the peptides. To explore more thoroughly this possibility,
let us define a (combinatorial chemistry) protocol P by a l-tuple containing, for
each position i in the peptide of length l, an independent distribution Pi(a) over
the 20 amino acids a ∈ A. Hence, we define a protocol by
P
def
= (P1, . . . ,Pl) . (10)
Consequently, the peptides produced by this protocol will be distributed follow-
ing the joint distribution P1 × . . .× Pl. Hence, the probability of synthesizing
a peptide is given by
P (x) =
|x|∏
i=1
Pi(xi) . (11)
This family of protocols is easy to implement in the laboratory since, at each
step i, it only requires splitting the content of the pooling reactor in proportion
equal to the distribution Pi over amino acids.
3.5 Expected outcome of a library given a protocol
We present a method for efficiently computing exact statistics on the outcome of
a protocol P . More precisely, we present an algorithm to compute the average
bioactivity and its variance over all peptides that a protocol can synthesize.
Note that we cannot compute these statistics by simply predicting the activity
of each peptide since the set of all possible peptides of length l is simply too
large.
Such statistics will assist chemists in designing a protocol with a greater hit
ratio and avoid superfluous experiments increasing cost. Indeed, the count of all
possible peptides will help to choose the right amount of peptide-coated beads
in the assay. Moreover, the average bioactivity will help designing a protocol
that synthesizes as many potential active candidates as possible. Finally, the
bioactivity variance will allow to control the exploration/exploitation trade off
of the experiment.
The proposed approach makes use of the graph Gn, the protocol P , and a
dynamic programming algorithm that exploits recurrences in the factorization
of first and second order polynomials to efficiently compute the following two
11
Figure 1: Iterative process for the design of peptide ligand.
quantities:
τ
def
=
∑
x∈Al
P (x) · h(x,y)
β
def
=
∑
x∈Al
P (x) · h(x,y)2 .
Indeed, the average and variance bioactivity of peptides synthesized by the
protocol are then respectively given by τ and β − τ2. The algorithm and its
details are given in Section 6.3 (supplementary material).
3.6 Application in combinatorial drug discovery
We propose an iterative process to accelerate the discovery of bioactive peptide.
The procedure is illustrated in Figure 1. First, an initial set of random peptides
is synthesized, typically using a split and pool approach. Then peptides are
assayed in laboratory to measure their bioactivities. At this point most peptides
are poor candidates. They are then used as a training set to produce a predictor
h. Then h is used for the generation of K bioactive peptides by finding the K-
longest paths in Gn as described previously. After, a protocol that consists of
using for each position, amino acids with equal proportion in which they appear
in the K lead compounds is used to synthesize a large array of potential active
peptides. The algorithm described in Section 3.5 is then used to predict the
statistics of the assay. This ensures that the protocol meets the expectations
in terms of quality (average bioactivity) and diversity (bioactivity variance).
To lower the cost, we proceed to synthesize and test the peptides only if the
expectations are met. This process can be repeated until the desired bioactivity
is achieved.
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3.7 Peptide synthesis, bacterial strains and minimal in-
hibitory concentration assay
Peptides were synthesized on a Prelude Peptide Synthesizer (Protein Technolo-
gies Inc, AZ) using standard Fmoc solid phase peptide chemistry (Wellings and Atherton,
1997). Briefly, the synthesis was performed on Rink Amide AM resin and the
amino acid couplings achieved with HCTU/NMM. The peptides were cleaved
from the resin using a mixture of 95% trifluoroacetic acid, 5% triisopropylsi-
lane, 5% water for 3h at room temperature and precipitated in cold diethyl
ether. After triturating for 2 min, the peptides were collected upon centrifuga-
tion and decantation of the ether. The peptides were purified on a Vydac C18
reversed-phase HPLC column (22 × 250 mm, 5µm) over 20 min using a linear
gradient of 10− 90% acetonitrile with 0.1% trifluoroacetic acid at a flow rate of
10 mL/min with optical density monitoring at 220 nm. The collected fractions
were lyophilised and the identity and purity of the peptides assessed by ana-
lytical HPLC and MALDI-TOF mass spectrometry. Peptides were obtained in
good yields and with purity greater than 90%.
Escherichia coli K12MG1655 and Staphylococcus aureus 68 (HER1049) were
obtained from the Fe´lix d’He´relle Reference Center for Bacterial Viruses of Uni-
versite´ Laval (www.phage.ulaval.ca). Both strains were grown in Trypticase
soy broth with agitation at 37◦C. The minimal inhibitory concentration assay
was performed as described in Wiegand et al. (2008). The broth microdilution
protocol performed in 96-well plates. The bacterial strains were grown overnight
at 37◦C with aeration and diluted to a final concentration of 5× 105 cfu/ml in
the assay. The peptides were diluted in sterile water and were tested at the fol-
lowing concentrations: 0, 1, 2, 4, 8, 16 and 32 µg/ml. The optic density (600nm)
was followed every 30 minutes for 24 hours in a Synergy 2 plate reader (BioTek
Instruments, Inc.).
4 Result and Discussion
4.1 Data
Two public datasets were used to test and validate our approach. The first
dataset consisted of 101 cationic antimicrobial pentadecapeptides (CAMPs)
from the SAPD database (Wade and Englund, 2002). Peptide antibacterial ac-
tivities are expressed as the logarithm bactericidal potency which is the aver-
age potency over 24 bacteria such as Escherichia coli, Bactero¨ıdes fragilis, and
Staphylococcus aureus. The average antibacterial activity was 0.39 and the best
peptide had an activity of 0.824.
The second dataset consisted of 31 bradykinin-potentiating pentapeptides
(BPPs) reported by Ufkes et al. (1982). The bioactivities are expressed as the
logarithm of the relative activity index compared to the peptide VESSK. The
average bioactivity was 0.71 and the best peptide had an activity of 2.73.
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Figure 2: The K-longest path algorithm was used to rank the 100, 000 peptides
with highest anti-microbial activity. We observed a smooth power law with few
exceptional peptides.
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4.2 Improving the bioactivity of peptides
To assess the capability of our approach to improve upon known peptides, that
is, to predict peptides with superior biological activities to the known ones,
we carried out the following experiment using the CAMPs and BPPs peptide
datasets. First, a predictor of biological activity was learned by kernel ridge
regression (KRR) for both datasets. Hyper-parameters for the GS kernel and
the KRR were chosen by standard cross-validation. Then, using the K-longest
path algorithm and the learned predictor, we generated the K peptides (of
the same length as those of the training data) having the greatest predicted
biological activity.
On the CAMPs dataset, our approach predicted that the peptide WWK-
WWKRLRRLFLLV should have an antibacterial potency of 1.09, a logarithmic
improvement of 0.266 over the best peptide in the training set (GWRLIKKIL-
RVFKGL, 0.824), and a substantial improvement over the average potency of
that dataset (average of 0.39). The anti-microbial activity of the top 100000
peptides are showed in Figure 2. As expected, we observe a smooth power law
with only a few peptides having outstanding biological activity.
On the BPPs dataset, our approach predicted that the pentapeptide IEWAK
should have an activity of 2.195, slightly less than the best peptide of the training
set (VEWAK, 2.73, predicted as 2.192). However, the predicted activity of
IEWAK is much better than the average peptide activity of the dataset, which
is 0.71. One can ask why IEWAK has a lower biological activity than VEWAK
which was part of the training data? Machine learning algorithm are known
to be resistant to errors and noise in the data. A possible explanation for this
discrepancy is that the biological activity of VEWAK could be slightly erroneous
as the learning algorithm could not find a simple predictor given such an outlier.
In addition, VEWAK was predicted an activity of 2.192 in spite of been seen
during training with an activity of 2.73. It seems that, given the data, the
activity of IEWAK is more easily justified than of VEWAK.
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4.3 Application in drug discovery
When facing a new target, there is typically none to little information on pep-
tides that could bind to the target protein. To gather some information, the
standard approach is to synthesize a library of random peptides and measure,
for each candidate, the desired biological activity. Typically, this will only yield
a few candidates. The proposed approach has the capability of extracting rel-
evant information from weak candidates and in an iterative manner, predict
stronger ones.
As a proof of concept, we propose to replace the laboratory experiment in the
proposed procedure by a predictor learned on available datasets. We will refer
to this predictor as the “expert”, since it encapsulates the current knowledge
about the studied problem. The expert predictor is only used to determine the
activities of the peptides generated in the initial random screening phase and
those generated by our approach. To prevent bias, once the expert predictor
is learned, the dataset is hidden from the process. Then, we randomly draw
peptides and, instead of testing them in lab, we use the expert predictor to
determine their activities. At this point most peptides are very weak candidates.
A student predictor is learned with the weak peptides serving as the training
data. We then use the K-longest path approach and the student predictor to
predict improved compounds. To validate that peptides predicted (or generated)
by this student predictor are indeed relevant, we then validate them with the
expert predictor. Recall that the expert predictor was only used to determine
the activity of the randomly generated peptides.
This proof of concept was conducted twice on both the CAMPs and the
BPPs datasets. Once by drawing 100 random peptides, and then by drawing
1000 random peptides at the initial screening stage. The results are shown in
Table 1. As expected, the number of drawn peptides had no significant effect
on the average activity on both datasets. On both datasets, the number of
random peptides had no significant effect on the best peptide found, supporting
the development of new techniques to facilitate the discovery of high activity
compounds.
Using the proposed approach and the same 100 random peptides to train
the student predictor, we were able to reach an antimicrobial potency of 0.83,
similar to the best peptide of the CAMPs dataset. By increasing to 1000 training
peptides, we found a peptide having a predicted potency of 1.09, surpassing the
best known peptide. On the BPPs dataset, the proposed approach considerably
outperformed the random peptides method on both the best peptide found and
the average bioactivity. Finally, on both datasets, increasing the number of
initial peptides from 100 to 1000 had a stronger positive effect than the random
approach: 0.26 increase in potency for CAMPs and 0.16 increase for BPPs.
4.4 Binding motifs results
To demonstrate the ability of the proposed approach to predict potential func-
tional motifs, we took further the proof of concept proposed in the previous
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Table 1: Results from the drug discovery simulation. Comparison between the
standard combinatorial screening (random peptides) and the proposed approach
(longest paths).
Random peptides Longest Paths
Dataset # of peptides Average Max. Average Max.
CAMPs 100 −0.58 0.17 0.76 0.83
1000 −0.59 0.18 1.07 1.09
BPPs 100 0.31 1.39 1.50 2.04
1000 0.26 1.36 1.66 2.20
section. As previously, we learned an expert predictor from the CAMPs dataset
which was then hidden for the rest of the procedure. Using the expert predic-
tor, we predicted the best 103 peptides and produced a bioactivity motif using
theses candidates (top panel of Figure 3). Our goal was to assess how much of
that reference motif could we rediscover if we were to hide all of the CAMPs’
dataset. Next, we drew 1000 random peptides and use the expert predictor to
determine their activities. Theses peptides have, as illustrated in Table 1, on
average, very weak antimicrobial potency. As previously, we learned a student
predictor using the random peptides as training data and generated, according
to the student predictor, the best 1000 candidates. The motif obtained from
theses candidates is shown in the middle panel of Figure 3.
We were able to recover all of the reference motif signal using only weakly ac-
tive peptides. This provides evidence that the proposed approach could uncover
complex signals for new, poorly understood, proteins. To push the analysis even
further, we decreased the number of peptides used to train the student predic-
tor to 100 training examples. Even then, for 12 residue positions, we were able
to correctly identify the dominant amino acid property (polar, neutral, basic,
acidic, hydrophobic). This is achieved since the GS kernel encodes amino acids
physico-chemical properties.
To put these results in perspective, we took the same peptides used to train
the student predictor and generated a motif from them. The resulting signal
was very poor, generating a meaningless motif. We had to draw 106 random
peptides and select the best 103 to produce a motif with minimal information
(Figure 3 bottom panel). This clearly illustrates the potential of the proposed
approach for accelerating the discovery of potential peptidic effectors.
4.5 In vitro antimicrobial assay
A total of 12 peptides were synthesized. The two most active peptides of the
CAMPs dataset (Peptide #5 and #6) were used for comparison. We also se-
lected one peptide with poor activity (Peptide #7) as a control. The proposed
machine learning approach was used to generate a list of 1000 putative candi-
dates with the highest predicted activity. From this list, we selected three com-
pounds in a way to maximize the chemical diversity among chosen compounds.
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Figure 3: CAMP bioactivity motifs. Top motif: obtained from the 103 best
candidates generated by the expert predictor. Middle motif: obtained from
the 103 best candidates generated by the student predictor. Bottom motif:
obtained from the best 103 candidates out of 106 random peptides.
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Table 2: Minimal inhibitory concentration (MIC) resulting from the in vitro
CAMPs assay.
MIC (µg/ml)
# Peptide sequence E. coli S. aureus
1 YWKKWKKLRRIFMLV 2 8
2 WWKRWKKLRRIFLML 4 4
3 WWKRWKRIRRIFMMV 4 8
4 WWKWWKRLRRLFLLV 16 16
5 KWKLFKGIRAVLKVL 4 8
6 GWRLIKKILRVFKGL 4 4
7 KWKLFLGILAVLKVL > 32 > 32
We then tested these peptides (Peptide #2, #3, #4) with a high throughput
growth inhibitory assay as described in Section 3.7. Results from the minimal
inhibitory concentration assay are shown in Table 2. Two of the three candi-
dates have activities equal to the best candidate of the CAMPs dataset. We
were intrigued by the failure of Peptide #4 and after investigation verified that
the poor performance was due to poor water solubility. In a second series, we
ensured that a filter for water solubility was employed. In this second series of
tests, Peptide #1 showed (at least against E. coli) better activity than any of
the original candidates from the CAMPs dataset, demonstrating that, in this
limited biological experiment, we could improve the putative candidates using
the proposed machine learning methodology.
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5 Conclusion and Outlook
We proposed an efficient graph-theoretical algorithm that predicts the peptides
with the highest biological activities for machine learning predictors using the
GS kernel. We showed how this algorithm can also be used to predict the bind-
ing motif for a target with no known ligands. This is feasible thanks to the
multi-target model which is capable of exploiting similarities with related pro-
teins that share common structures. To increase the hit ratio of combinatorial
libraries, we have demonstrated how a combinatorial chemistry protocol relates
to a motif distribution. This allowed us to compute the expected bioactivity and
its variance that can be exploited by a combinatorial chemistry protocol such
as a one bead one compound protocol. These steps can be part of an iterative
drug discovery process that will have immediate use in both the pharmaceutical
industry and academia. This methodology will reduce costs and the time to
obtain lead compounds as well as facilitating their optimization. Finally, the
proposed approach was validated in a real world test for the discovery of new
antimicrobial peptides. These in vitro experiments confirmed the effectiveness
of the new compounds uncovered.
The K-best peptides were shown to be valuable for the design of split and
pool libraries of compounds. However, in such libraries, it is unclear how we
should prioritize high activity candidates (average) over the chemical diversity
(variance). This exploration/exploitation trade-off could be examine in future
work. Moreover, recent advances in domain-adaptation machine learning could
possibly improve the accuracy of the learned predictor since the data generating
and the testing distributions are both known. Finally, the method could be
expanded to cyclic peptides and chemical entities (building blocks) of common
structure found in clinical compounds.
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6 Supplementary material
6.1 Algorithm for the longest path
Recall that, by definition,
W (s, i)
def
=
m∑
q=1
βq(y)
k∑
p=1
|xq|−p∑
j=0
e
(
−((i−1)−j)2
2σ2p
)
× e
(
−‖ψp(s1,...,sp)−ψ
p(xq [j+1],..,xq [j+p])‖
2
2σ2c
)
,
and
Wt
(
(s, i), t
) def
=
k−1∑
j=1
W (sj+1 . . . sk, n+ j) .
The pseudo-code for the longest path algorithm is given by Algorithm 1.
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Algorithm 1 Find the longest path in Gn between the source node (λ, 0) and
the sink node t.
length to = array with n|A|k + 2 entries initialized to −∞
predecessor = array with n|A|k + 2 entries
for all a ∈ Ak do ⊲ Edges leaving the source node
length to[a, 1]←W (a, 1)
end for
for i = 2→ n do ⊲ Edges from the core of Gn
for all a ∈ Ak do
for all a′ ∈ A do
s← a2, . . . , ak, a
′ ⊲ Note that |s| = k
if length to[s, i] ≤length to[a, i− 1] +W (s, i) then
length to[s, i]← length to[a, i− 1] +W (s, i)
predecessor[s, i]← a
end if
end for
end for
end for
max length← −∞
longest path← λ
for all a ∈ Ak do ⊲ Edges heading to the sink node
if max length ≤ length to[a, n] +Wt((a, n), t) then
max length← length to[a, n] +Wt((a, n), t)
longest path← a
end if
end for
for i = n→ 2 do ⊲ Backtrack using the predecessors
a1, . . . , ak ← predecessor[longest path[1:k], i]
longest path← a1, longest path
end for
return longest path
6.2 Algorithm for finding the K-longest paths
The algorithm uses a trivial variant of the longest path algorithm, given in
Section 6.1, that allows a path to start from any node of the graph. The pseudo
code is given by Algorithm 2.
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Algorithm 2 Find the K-longest paths in Gn
A = array with K entries initialized with the empty string
B = max-heap to store potential paths and their lengths
A[0]← LongestPath
(
Gn, (λ, 0), t
)
for i = 0→ K − 1 do
for all (a, j) ∈
(
(λ, 0), (A[i][0:k], 1), .., (A[i][l−k:l], n)
)
do ⊲ Nodes of the
previous path
(V,E)← Gn
root ← A[i][0:j+k]
for r = 0→ i do
if A[r][0:j+k] = root then
E ← E \ (A[r][j:j+k] , j)
end if
end for
x← root + LongestPath
(
(V,E), (a, j), t
)
if x /∈ B ∪ A then
B.push
(
x, h(x, y)
)
⊲ Add the string and it’s length to the
max-heap
end if
end for
A[i + 1]← B.pop() ⊲ B’s longest path becomes the i-th longest path
end for
return A
6.3 Algorithm for computing the combinatorial library
statistics
To compute the statistics efficiently, the dynamic programming algorithm, given
by Algorithm 3, uses the following simple recurrence relations.
n∑
i=1
xi = xn +
n−1∑
i=1
xi , (12)
and (
n∑
i=1
xi
)2
=
(
n−1∑
i=1
xi
)2
+ 2xn
(
n−1∑
i=1
xi
)
+ x2n . (13)
Moreover, each node of the graph Gn has the following additional variables.
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• τ [s, i] for the expected length of paths from the source to the node (s, i).
• β [s, i] for the expected squared length of paths from the source to the node
(s, i).
• ρ[s, i] for the sum of probabilities given by all possible paths from the
source the node (s, i).
After executing the dynamic programming algorithm, the values of τ and β are
respectively set to τ [t] and β [t] for the sink node t. Finally, recall that Pi(a) is
the probability of having amino acid a at position i in a peptide.
Algorithm 3 Compute statistics using Gn and P
τ ,β,ρ : arrays with n|A|k + 2 entries initialized to 0
for all a ∈ Ak do ⊲ Edges leaving the source node
τ [a, 1]← P1(a1)W ((λ, 0), (a, 1))
β [a, 1]← P1(a1)W ((λ, 0), (a, 1))
2
ρ[a, 1]← P1(a1)
end for
for i = 2→ n do
for all a ∈ Ak do
for all a′ ∈ A do ⊲ Visiting edge ((a, i− 1), (s, i))
s← a2, . . . , ak, a
′
τ [s, i]+ = Pi(a2)
(
τ [a, i− 1] + ρ[a, i− 1]W ((a, i− 1), (s, i))
)
β [s, i]+ = Pi(a2)
(
β [a, i−1]+ρ[a, i−1]W ((a, i−1), (s, i))2+2τ [a, i−
1]W ((a, i− 1), (s, i))
)
ρ[s, i]+ = Pi(a2)ρ[a, i− 1]
end for
end for
end for
for all a ∈ Ak do ⊲ Edges heading to the sink node
r ←
∏k−1
i=1 Pn+i(ai+1)
τ [t]+ = r
(
τ [a, n] + ρ[a, n]Wt((a, n), t)
)
β [t]+ = r
(
β [a, n] + ρ[a, n]Wt((a, n), t)
2 + 2τ [a, n]Wt((a, n), t)
)
ρ[t]+ = rρ[a, n]
end for
return τ [t], β [t]
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